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the care: 78% recommend swimming; 68% regular walks; 55%
yoga; 27% stretching and 23% bicycling. CONCLUSIONS:
FMS is a frequently diagnosed illness in general medicine (6 FMS
patients/GP). The difﬁculties in treating the illness seem evident
as shown by the multiple therapeutic choices. We may note the





RELATIONSHIPS BETWEEN AGE, NUMBER OF
PRESCRIPTIONS,AND CO-MORBIDITIES AMONG VA
PATIENTS
Raisch DW, Harris CL, Netravali S, Campbell H
VA Cooperative Studies Program, Albuquerque, NM, USA
OBJECTIVE: To determine the relationship between the Charl-
son co-morbidity index and age and annual number of pre-
scriptions dispensed among a sample of Veterans Affairs 
(VA) patients receiving nonsteroidal anti-inﬂammatory agents
(NSAIDs). METHODS: NSAID patients treated at three VA
medical centers were identiﬁed from a previous study. Prescrip-
tion records, demographics, and International Classiﬁcation of
Disease-9 (ICD-9) diagnoses were obtained from the VA elec-
tronic databases. The comorbidity index for each patient was
determined by applying appropriate weights to ICD-9 diagnoses
and summing the weights for each patient. We applied stepwise
regression with co-morbidity index as the dependent variable
and age and number of prescriptions as independent variables.
We used VA-1 as the pilot study, to determine if a relationship
existed between the variables. We performed the same analyses
using the additional two medical centers to validate the rela-
tionship. RESULTS: There were 17,893 patients included in the
study, 7322 at VA-1, 6094 at VA-2, and 4447 at VA-3. Mean
ages ± standard deviations (SD) were 59.5 ± 13.3, 58.4 ± 13.0,
and 62.5 ± 13.1, respectively. Mean annual numbers of pre-
scriptions (±SD) were 33.6 ± 31.7, 31.8 ± 29.9, and 47.9 ± 39.5,
respectively. Mean comorbidity weights (±SD) were 2.1 ± 2.4,
1.5 ± 2.1, and 1.6 ± 1.9, respectively (p < 0.001). Stepwise regres-
sion results, with comorbidity as the dependent variable, were
signiﬁcant (p < 0.001) for age and number of prescriptions and
explained 20.2%, 16.7%, and 14.4% of the variance. When data
were combined and VA medical center was included, the model
explained 18.8% of the variance (p < 0.001 for medical center,
age and number of prescriptions). The adjusted mean comor-
bidity weights by VA medical center were 2.2 (standard error
(SE) = 0.023), 1.6 (SE = 0.25) and 1.3 (SE = 0.30) respectively.
CONCLUSION: Among VA NSAID patients, the annual
number of prescriptions, medical center, and age are strongly
related to the Charlson co-morbidity index.
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OBJECTIVES: The objective of this study is to cross-validate a
new questionnaire designed to predict the future risk of NSAID-
induced gastrointestinal events against a standard questionnaire,
the GI SCORE survey. METHODS: Four-hundred consenting,
consecutive patients from a rheumatology clinic in the mid-
western United States were administered both questionnaires.
The questionnaires were not administered in any particular
order. The new questionnaire contains questions that are similar
to ﬁve of six questions found in GI SCORE, in addition to ﬁve
questions not found in GI SCORE. The completed GI SCORE
questionnaires were scored and the associated risk levels were
determined. Feasible generalized least squares (FGLS) and multi-
nomial logistic (MNL) regression were used to map the ques-
tions from the new questionnaire onto the scores and two
different groups of risk levels, respectively, determined from GI
SCORE. Based on the results of the FGLS analysis, a scoring
scheme was created for the new questionnaire, allowing the pre-
diction of risk levels similar to GI SCORE. Risk levels generated
from both FGLS and MNL were compared to those predicted
by GI SCORE. RESULTS: For FGLS, the new questionnaire pre-
dicted risk levels that matched those predicted by GI SCORE
with 83% accuracy. When the original 4 risk levels predicted by
GI SCORE were collapsed into 3 risk levels, with the 2 most
severe risk levels becoming a single risk level, the predictions
from the new questionnaire were 89% accurate. For MNL, the
new questionnaire was 76% and 87% accurate for four and
three risk levels, respectively. CONCLUSIONS: The new ques-
tionnaire appears to be reasonably accurate in predicting the
same risk as those predicted by a standard survey. FGLS is
slightly more accurate than MNL in predicting risk for both
groups of risk considered.
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OBJECTIVE: To construct a ﬂexible and transparent pharma-
coeconomic model to assess the value of COX-2 selective
inhibitors (COX-2s) in the treatment of arthritis. METHODS:
Literature searches and interviews with Health Care practition-
ers were conducted to identify critical issues for model con-
struction. Model assumptions and parameters estimates for the
new COSMO model were made based on these efforts. Conver-
gent validity was assessed by comparing COSMO model outputs
to results obtained using previously published models, when
similar inputs were used in each model. RESULTS: Because
arthritis patients often switch medications, the COSMO model
simulates treatment strategies, rather than individual drugs.
COSMO allows users to compare strategies under which patients
start on an NSAID or COX-2 and switch medications twice. It
was structured as a one-month cycle Markov model with the fol-
lowing disease states: GI discomfort, loss of efﬁcacy, complicated
ulcer, uncomplicated ulcer, CV event, no events, and death.
Inputs allowed for different levels of complexity to address the
difﬁculty in obtaining data sources in different countries. Multi-
ple clinical (number of deaths, GI discomfort, ulcers, uncon-
trolled arthritis) and economic (drug costs, costs of managing GI
and CV events, total costs) outputs were included. Monte Carlo
simulations, acceptability curves, cost-effectiveness planes and
extensive univariate and multi-variate sensitivity analysis can be
performed with any input. For base case analyses, we assume a
3rd party payer perspective. In the validation exercise, we
applied inputs from a published model (Maetzel et al., 2003),
and obtained similar results (7% variation) and similar trends 
in sensitivity analyses, suggesting strong convergent validity.
CONCLUSIONS: COSMO is a pharmacoeconomic model 
that assesses the value of different treatment strategies for
